|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Operating expenses: | |||||
| Research and development | |||||
| General and administrative | |||||
| Impairment of long-lived assets | |||||
| Total operating expenses | |||||
| Loss from operations | |||||
| Change in fair value of common warrant liability | |||||
| Interest and other income, net | |||||
| Net loss | |||||
| Other comprehensive loss: | |||||
| Unrealized gain on investments, net | |||||
| Comprehensive loss | |||||
| Net loss per common share, basic | |||||
| Net loss per common share, diluted | |||||
| Weighted-average number of common shares used to compute basic net loss per common share | |||||
| Weighted-average number of common shares used to compute diluted net loss per common share | |||||
Loading...